M. Takeyama (1), H. Wakabayashi (1), P. J. Fay (1)
(1) Department of Biochemistry and Biophysics, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Although factor (F) VIIIa is inactivated by activated protein C (APC) through cleavages in the FVIII heavy chain-derived A1 (Arg 336) and A2 subunits (Arg 562, the FVIII light chain (LC) contributes to catalysis by binding the enzyme. ELISA-based binding assays showed that FVIII and FVIII LC bound to immobilised active site-modified APC (DEGR-APC) (apparent Kd ~270 nM and 1.0 μM, respectively). Fluid-phase binding studies using fluorescence indicated an estimated Kd of ~590 nM for acrylodan-labelled LC binding to DEGR-APC. Furthermore, FVIII LC effectively competed with FVIIIa in blocking APC-catalysed cleavage at Arg336 (Ki = 709 nM). A binding site previously identified near the C-terminal end of the A3 domain (residues 2007–2016) of FVIII LC was subjected to Ala-scanning mutagenesis. FXa generation assays and western and dot blotting were employed to assess the contribution of these residues to FVIIIa interactions with APC. Virtually all variants tested showed reductions in the rates of APC-catalysed inactivation of the cofactor and cleavage at the primary inactivation site (Arg336), with maximal reductions in inactivation rates (~3-fold relative to WT) and cleavage rates (~3 to ~9-fold relative to WT) observed for the Met2010Ala, Ser2011Ala, and Leu2013Ala variants. Titration of FVIIIa substrate concentration monitoring cleavage by a dot blot assay indicated that these variants also showed ~3-fold increases relative to WT while a double mutant (Met2010Ala/Ser2011Ala) showed a >4-fold increase in Km. These results show a contribution of a number of residues within the 2007–2016 sequence, and in particular residues Met2010, Ser2011, and Leu2013 to an APC-interactive site.
activated protein C, proteolysis, factor VIIIa, factor VIII mutants
Matus Rehak1,2, Jiri Rehak2, Marc Müller3, Susanne Faude1, Frank Faude1, Annelie Siegemund4, Vera Krcova5, Ludek Slavik5, Dirk Hasenclever6, Markus Scholz6, Peter Wiedemann1
Thromb Haemost 2008 99 5: 925-929
Carolyn M. Millar1, Anne F. Riddell1, Simon A. Brown1, Richard Starke2, Ian Mackie2, Derrick J. Bowen3, P. Vincent Jenkins1, Jan A. van Mourik4
Thromb Haemost 2008 99 5: 916-924
Anette L. Eilertsen1,2, Sigurd Liestøl1, Marie-Christine Mowinckel1, H. Coen Hemker3, Per-Morten Sandset1,2
Thromb Haemost 2007 97 6: 938-943
Patients receiving oral anticoagulants should be carefully managed to minimize the risk of bleeding...
Acquired haemophilia A (AHA) is a rare but often severe bleeding disorder caused by ...
Section III " Vitamin K antagonists in heart disease: Current status and perspectives" of...